94.85
price up icon0.51%   0.48
after-market After Hours: 94.85
loading
Merus N V stock is traded at $94.85, with a volume of 2.30M. It is up +0.51% in the last 24 hours and up +36.32% over the past month. Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$94.37
Open:
$94.45
24h Volume:
2.30M
Relative Volume:
1.26
Market Cap:
$7.17B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-24.01
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+0.62%
1M Performance:
+36.32%
6M Performance:
+125.99%
1Y Performance:
+77.62%
1-Day Range:
Value
$94.38
$95.02
1-Week Range:
Value
$94.24
$95.02
52-Week Range:
Value
$33.19
$95.02

Merus N V Stock (MRUS) Company Profile

Name
Name
Merus N V
Name
Phone
31 030 253 8800
Name
Address
YALELAAN 62, 3584 CM UTRECHT
Name
Employee
260
Name
Twitter
@MerusNV
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
MRUS's Discussions on Twitter

Compare MRUS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MRUS
Merus N V
94.85 7.15B 35.93M -244.56M -157.31M -3.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Merus N V Stock (MRUS) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-17-25 Initiated Barclays Overweight
Aug-25-25 Initiated Alliance Global Partners Buy
Feb-13-25 Initiated Piper Sandler Overweight
Feb-07-25 Initiated Wells Fargo Overweight
Nov-21-24 Initiated Goldman Buy
Oct-24-24 Initiated UBS Buy
Mar-28-24 Initiated Truist Buy
Mar-04-24 Reiterated Needham Buy
Nov-02-23 Initiated Canaccord Genuity Buy
Aug-21-23 Initiated TD Cowen Outperform
Aug-02-22 Initiated Stifel Buy
Feb-11-22 Initiated BMO Capital Markets Outperform
Feb-10-22 Initiated Needham Buy
Nov-17-21 Resumed Guggenheim Buy
Jun-07-21 Upgrade Citigroup Neutral → Buy
Apr-08-21 Initiated William Blair Outperform
Mar-16-21 Initiated SVB Leerink Outperform
Jun-26-20 Initiated H.C. Wainwright Buy
May-27-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-20-19 Resumed Guggenheim Buy
Jun-28-19 Initiated ROTH Capital Buy
Apr-12-19 Resumed Guggenheim Buy
Apr-03-19 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-27-19 Initiated Berenberg Buy
Jan-02-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-15-17 Initiated RBC Capital Mkts Outperform
Mar-21-17 Downgrade Citigroup Buy → Neutral
Dec-22-16 Upgrade Citigroup Neutral → Buy
Nov-07-16 Downgrade Citigroup Buy → Neutral
Jun-13-16 Initiated Citigroup Buy
Jun-13-16 Initiated Guggenheim Buy
Jun-13-16 Initiated Wedbush Outperform
View All

Merus N V Stock (MRUS) Latest News

pulisher
12:51 PM

Merus to present petosemtamab data for colorectal cancer at conference By Investing.com - Investing.com South Africa

12:51 PM
pulisher
12:10 PM

Merus N.V. to Present Two Abstracts on Petosemtamab at AACR-NCI-EORTC Conference in Boston - Quiver Quantitative

12:10 PM
pulisher
12:01 PM

Merus Announces Petosemtamab in Metastatic Colorectal - GlobeNewswire

12:01 PM
pulisher
12:00 PM

Phase 2 interim data: Merus' petosemtamab to be presented in plenary at AACR Oct 24; poster on cancer stem cells - Stock Titan

12:00 PM
pulisher
11:48 AM

Will Merus N.V. outperform the market2025 Trading Recap & High Accuracy Trade Signal Alerts - newser.com

11:48 AM
pulisher
11:06 AM

Will Merus N.V. stock deliver better than expected guidance2025 Macro Impact & Technical Confirmation Alerts - newser.com

11:06 AM
pulisher
11:03 AM

Can you recover from losses in Merus N.V.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com

11:03 AM
pulisher
10:44 AM

Why Merus N.V. is moving today2025 Big Picture & Breakout Confirmation Trade Signals - newser.com

10:44 AM
pulisher
10:00 AM

Can Merus N.V. stock double in next 5 yearsTrade Exit Summary & Stepwise Trade Signal Implementation - newser.com

10:00 AM
pulisher
09:10 AM

Will Merus N.V. stock sustain high P E ratiosJuly 2025 Weekly Recap & Weekly High Potential Alerts - newser.com

09:10 AM
pulisher
06:50 AM

Deals In Depth: September 2025 - insights.citeline.com

06:50 AM
pulisher
Oct 11, 2025

Merus N.V. announces proposed public offering of common shares - MSN

Oct 11, 2025
pulisher
Oct 11, 2025

Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN

Oct 11, 2025
pulisher
Oct 11, 2025

Merus (NASDAQ:MRUS) Hits New 12-Month HighHere's Why - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Automated trading signals detected on Merus N.V.July 2025 Outlook & Low Risk High Win Rate Picks - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Merus N.V. (2GH) stock safe for risk averse investorsWall Street Watch & Accurate Entry/Exit Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

What margin trends mean for Merus N.V. stockNew Guidance & Daily Price Action Insights - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Merus NV a good long term investmentTrading Psychology Tips & Market Monitoring and Alerts - earlytimes.in

Oct 10, 2025
pulisher
Oct 09, 2025

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders - GlobeNewswire Inc.

Oct 09, 2025
pulisher
Oct 09, 2025

Merus NV stock hits all-time high at 94.56 USD By Investing.com - Investing.com Nigeria

Oct 09, 2025
pulisher
Oct 09, 2025

Merus NV stock hits all-time high at 94.56 USD - Investing.com

Oct 09, 2025
pulisher
Oct 09, 2025

Will Merus N.V. stock see PE expansion2025 Short Interest & Real-Time Volume Spike Alerts - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Why Merus N.V. (2GH) stock could outperform next yearJuly 2025 Movers & Reliable Entry Point Alerts - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise - Investing.com Nigeria

Oct 08, 2025
pulisher
Oct 08, 2025

Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise By Investing.com - Investing.com South Africa

Oct 08, 2025
pulisher
Oct 07, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Oct 07, 2025
pulisher
Oct 07, 2025

Oklahoma City NewsThe Oklahoman - FinancialContent

Oct 07, 2025
pulisher
Oct 07, 2025

Merus (NASDAQ:MRUS) Downgraded by Leerink Partnrs to "Hold" - MarketBeat

Oct 07, 2025
pulisher
Oct 06, 2025

GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com

Oct 06, 2025
pulisher
Oct 06, 2025

Truist Securities raises Genmab stock price target to $49 on Merus acquisition - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Is Merus N.V. building a consolidation baseQuarterly Profit Review & Short-Term High Return Strategies - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Leerink Partners Downgrades Merus to Market Perform From Outperform, Adjusts PT to $97 From $95 - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

MRUS Downgraded to Market Perform by Leerink Partners with Raise - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

What MACD signals say about Merus N.V.Profit Target & Consistent Profit Alerts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Leerink Partners downgrades Merus stock to Market Perform on Genmab deal - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

What’s the recovery path for long term holders of Merus N.V.2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

How big funds are accumulating Merus N.V. (2GH) stockRecession Risk & Verified Entry Point Detection - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Relative strength of Merus N.V. in sector analysisJuly 2025 Recap & Fast Entry Momentum Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Merus N.V. (2GH) stock maintain strong growth2025 Institutional Moves & Community Verified Swing Trade Signals - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion - MSN

Oct 03, 2025
pulisher
Oct 03, 2025

Genmab acquires Merus for $97 per share in cash or $8B - MSN

Oct 03, 2025
pulisher
Oct 03, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRU - GuruFocus

Oct 03, 2025
pulisher
Oct 03, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, VECO on Behalf of Shareholders - cnhinews.com

Oct 03, 2025
pulisher
Oct 03, 2025

Truist raises Genmab stock price target to $49 on Merus acquisition - Investing.com

Oct 03, 2025
pulisher
Oct 03, 2025

Custom strategy builders for tracking Merus N.V.Market Sentiment Summary & Daily Profit Focused Screening - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Will Merus N.V. stock continue upward momentum2025 Big Picture & Technical Entry and Exit Alerts - newser.com

Oct 03, 2025

Merus N V Stock (MRUS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Merus N V Stock (MRUS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Silverman Peter B.
COO & GC
Jul 17 '25
Sale
60.00
25,000
1,500,000
0
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):